Valuation dashboard for Repligen Corporation (RGEN) with P/E 256.08, P/B 5.06, EV/EBITDA 88.47 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
Analysis Summary
Repligen Corporation reported revenue of $738.3M in the most recent fiscal year, growing at a 5-year CAGR of 15.0%. Net income reached $48.9M, with a -4.0% 5-year CAGR.
Trailing-twelve-month margins: gross margin 51.1%, operating margin 8.3%, net margin 5.3%.
At the current price of $189.50, RGEN trades at a P/E of 256.08 and an ROE of 1.98%. Market capitalisation stands at $10.7B, placing it among large-cap names.
Balance sheet quality for RGEN: current ratio of 8.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 256.08 |
| Price / Book | 5.06 |
| EV / EBITDA | 88.47 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $26.40 |
| vs Current Price | -86.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RGEN | Repligen Corporation | $10.7B | 256.08 | 5.06 | 2.0% |
| MASI | Masimo Corporation | $9.4B | 124.97 | 11.91 | -21.0% |
| GMED | Globus Medical, Inc. | $10.2B | 19.04 | 2.15 | 11.8% |
| DVA | DaVita Inc. | $11.5B | 15.70 | -123.6% | |
| BAX | Baxter International Inc. | $12.1B | 1.96 | -16.6% | |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 4.95 | -4.6% | |
| ATR | AptarGroup, Inc. | $7.7B | 21.41 | 2.91 | 14.7% |
| BIO | Bio-Rad Laboratories, Inc. | $10.2B | 44.31 | 1.38 | 3.2% |
Price
| Price | $189.50 |
| Market Cap | $10.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 1.98% |
| Return on Invested Capital | 1.83% |
| Return on Assets | 1.41% |
| Gross Margin | 51.05% |
| Operating Margin | 8.32% |
| Net Margin | 5.29% |
Related companies: ATR · AVTR · BAX · BIO · CRL · DVA · GMED
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of RGEN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks